Global HIV Drugs Market Growth 2023-2029

Global HIV Drugs Market Growth 2023-2029

HIV is a type of retrovirus that causes serious complications in humans. It generally spreads via the blood, semen, vaginal fluid, pre-ejaculate, or breast milk. The global market for HIV drugs is envisaged to surpass USD 19,000 million by 2019 owing to the recent rise in HIV patient population.

LPI (LP Information)' newest research report, the “HIV Drugs Industry Forecast” looks at past sales and reviews total world HIV Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected HIV Drugs sales for 2023 through 2029. With HIV Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world HIV Drugs industry.

This Insight Report provides a comprehensive analysis of the global HIV Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on HIV Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global HIV Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for HIV Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global HIV Drugs.

The global HIV Drugs market size is projected to grow from US$ 22880 million in 2022 to US$ 26430 million in 2029; it is expected to grow at a CAGR of 26430 from 2023 to 2029.

One of the primary factors catalyzing the growth of the global HIV drugs market is increase in the prevalence of HIV and its diagnosis. Apart from this, the market is also influenced by a rise in the number of government initiatives for spreading the awareness amongst people regarding causes, symptoms and treatments. Moreover, the introduction of generic drugs, which are cost-effective and chemically identical to branded drugs, act as another factor that is contributing towards the demand for HIV drugs.

This report presents a comprehensive overview, market shares, and growth opportunities of HIV Drugs market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
Multi-Class Combination Products
Nucleoside Reverse Transcriptase Inhibitors
Non-Nucleoside Reverse Transcriptase Inhibitors
Protease Inhibitors
Fusion Inhibitors
Entry Inhibitors - CCR5 Co-Receptor Antagonist
HIV Integrase Strand Transfer Inhibitors

Segmentation by application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bristol-Myers Squibb
Gilead Sciences
GlaxoSmithKline
Johnson & Johnson
Merck

Key Questions Addressed in this Report

What is the 10-year outlook for the global HIV Drugs market?

What factors are driving HIV Drugs market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do HIV Drugs market opportunities vary by end market size?

How does HIV Drugs break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.